Insider Selling: GSK plc (LON:GSK) Insider Sells 38,459 Shares of Stock

GSK plc (LON:GSK) insider Emma Walmsley sold 38,459 shares of the business’s stock in a transaction that occurred on Monday, February 17th. The stock was sold at an average price of GBX 1,418 ($17.94), for a total transaction of £545,348.62 ($690,139.99).

Emma Walmsley also recently made the following trade(s):

• On Monday, February 10th, Emma Walmsley sold 120,653 shares of GSK stock. The stock was sold at an average price of GBX 1,453 ($18.39), for a total transaction of £1,753,088.09 ($2,218,537.19).

GSK Stock Performance

Shares of LON:GSK opened at GBX 1,429 ($18.08) on Monday. GSK plc has a 52 week low of GBX 1,282.50 ($16.23) and a 52 week high of GBX 1,823.50 ($23.08). The company has a debt-to-equity ratio of 114.64, a current ratio of 0.81 and a quick ratio of 0.73. The company has a market capitalization of £57.99 billion, a P/E ratio of 23.08, a PEG ratio of 1.24 and a beta of 0.31. The firm has a 50 day moving average price of GBX 1,377.06.

GSK (LON:GSK) last issued its earnings results on Wednesday, February 5th. The company reported GBX 23.20 ($0.29) EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. On average, sell-side analysts forecast that GSK plc will post 175.980975 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on GSK shares. Berenberg Bank dropped their price target on shares of GSK from GBX 1,820 ($23.03) to GBX 1,600 ($20.25) and set a “buy” rating for the company in a research note on Friday, November 29th. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a research note on Tuesday, January 7th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of GBX 1,805.83 ($22.85).

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.